High dose rate brachytherapy for recurrent prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of high dose rate (HDR) brachytherapy as a salvage treatment for patients with recurrent prostate cancer following external beam radiotherapy. Patients with documented recurrence will undergo advanced imaging using multiparametric MRI to identify the site of recurrence, followed by a planning ultrasound to create a targeted treatment plan. The treatment involves delivering two fractions of HDR brachytherapy, with careful monitoring of patient outcomes, including toxicity and quality of life, over a two-year period. The study aims to evaluate the efficacy of this approach in achieving long-term cancer control.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>45 and Life expectancy \>10 years
* Previous External Beam Radiotherapy (EBRT) or LDR brachytherapy w
* \> 3 year interval since EBRT or LDR Brachytherapy
* No late toxicity from prior EBRT ≥ grade 2
* PSA \> nadir + 2 ng/ml and \< 10 ng/ml
* PSA Doubling time \> 6 months
* Radiographic evidence corresponding with site of recurrence in an under-dosed or untreated site. The recurrence should correspond to the site of original disease or be located in the seminal vesical +/- adjacent prostate as only area of recurrence (i.e. unifocal recurrence).
* Per Investigator, recurrence is suitable for implant with HDR brachytherapy and patient is suitable for procedure under anesthesia, spinal or general.
* Negative staging of the abdomen/pelvis and bones.
* Willing to provide informed consent

Exclusion Criteria:

* Not compliant with criteria above
* Unable to give informed consent

Where it's running

• BCCA Center for the Southern Interior
  Kelowna, British Columbia, Canada Recruiting

Study contacts

• Study coordinator: Juanita Crook, MD
• Email: jcrook@bccancer.bc.ca
• Phone: 2507123958

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IL-15 superagonist with or without a PSA vaccine in biochemically recurrent prostate cancer after SBRT

  This study tests whether the drug N-803, alone or with a PSA-targeted vaccine, can lower PSA in men with biochemically recurrent prostate cancer after prior SBRT.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07686380

• Terbinafine for prostate cancer with rising PSA after local treatment

  This phase II test gives oral terbinafine to men with biochemical recurrence after definitive local therapy and no visible metastases to see if it slows PSA rise and delays starting hormone therapy.

  Recruiting at 11 sites Phase 2 Swiss Cancer Institute · Baden and 10 other locations · NCT07365423

• DNA vaccine plus nivolumab and targeted radiation for recurrent oligometastatic prostate cancer

  This study will try a DNA vaccine called pTVG-HP together with the checkpoint blocker nivolumab and targeted radiation to see if they can eliminate metastatic tumors in men with non-castrate, recurrent oligometastatic prostate cancer.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT07090148

• Combining radiation therapy with hormone treatments for advanced prostate cancer

  This study is testing if combining a specific type of radiation therapy with hormone treatments can help men with advanced prostate cancer live longer and feel better compared to just using radiation alone.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT06378866

• Testing enzalutamide and PDS01ADC for recurrent prostate cancer

  This study is testing if a new combination of two treatments, enzalutamide and PDS01ADC, can help people with recurrent prostate cancer feel better and have better results than current options.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06096870

• Analyzing the tumor environment in metastatic prostate cancer

  This study is trying to learn more about the environment around prostate cancer tumors in men with advanced disease by looking at tissue samples to help find new treatment options.

  Recruiting Columbia University · New York, New York · NCT05304858

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.